Industry-Supported Symposia and Showcase Theatre
The following industry-supported symposia and showcase theater session are organized by sponsors of the 34th CINP World Congress of Neuropsychopharmacology and will be available during the 2023 Live Days.
Showcase Theatre
Title: Cerevel Therapeutics Pipeline Overview
Date: May 8th, 2023
Time: 10:15am – 10:45am
Venue: Foyer Theatre
Session Brief Description: Cerevel Therapeutics is advancing a broad and diverse neuroscience pipeline of small molecule therapies to address significant unmet medical needs and limited treatment options for patients suffering from some of the most prevalent neuroscience diseases. Dr. Ponton will give an update of Cerevel’s clinical pipeline comprised of multiple therapeutic candidates.
Speaker: Eric Ponton, PharmD, RPh, MBA. Sr. Director Medical Capabilities, Cerevel Therapeutics
Industry-Supported Symposia
Title: ISS01 – A Potential New TAARget for Schizophrenia Treatment: The Science behind TAAR1
Date: May 8th, 2023
Time: 1:30pm – 2:30pm
Room: Avenue Laurier Room
Speakers and Presentation Titles:
- Potential for TAAR1 Agonists in the Treatment of Schizophrenia
Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York, USA
Paid Consultant of Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. - Evolving our Understanding of Schizophrenia: Evidence for TAAR1 as a Potential Therapeutic Target in Preclinical Models
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine
Hofstra/Northwell, New York, USA
Paid Consultant of Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc.
Title: ISS02 – Our Evolving Understanding of Depression: From Monoamines to Neurocircuits
Date: May 9th, 2023
Time: 8:00am – 9:00am
Room: Avenue Laurier Room
Learning Objectives:
- Explore the neurobiology of depression beyond the monoamine hypothesis, with a focus on structural and functional changes in the brain
- Highlight the cognitive and emotional dysregulation that characterizes depression, as well as neurocircuits involved in specific symptom clusters
- Discuss current evidence for neuroplasticity as a treatment target for mood disorders, and the potential for digital therapeutics to leverage neuroplasticity.
Speaker: Joseph F. Goldberg M.D.
Title: ISS03 – Unmet Need in Schizophrenia and the Potential of Targeting the Glutamatergic System
Date: May 9th, 2023
Time: 1:30pm – 2:30pm
Room: Avenue Laurier Room
Agenda:
- Introduction (Christoph Correll, USA)
- Do negative symptoms and cognitive symptoms and cognitive impairment associated with schizophrenia demand more attention (Christoph Correll, USA)
- The next “next generation” in schizophrenia treatment? (John Krystal, USA)
- GlyT1 inhibition and the potential of combined approaches (Ofer Agid, Canada)
- Closing remarks and Panel Q&A (John Krystal, USA)
Co-chairperson:
- Christoph Correll (USA)
- John Krystal (USA)
Speaker:
- Ofer Agid (Canada)